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Resistance to DNA damage–induced apoptosis is a hallmark of cancer and a major cause of treatment failure and
lethal disease outcome. A tumor entity that is largely resistant to DNA-damaging therapies including chemo- or
radiotherapy is renal cell carcinoma (RCC). This study was designed to explore the underlying molecular
mechanisms of DNA damage resistance in RCC to develop strategies to resensitize tumor cells to DNA damage–
induced apoptosis. Here, we show that apoptosis-resistant RCC cells have a disconnect between activation of p53
and upregulation of the downstream proapoptotic protein p53 upregulated modulator of apoptosis (PUMA). We
demonstrate that this disconnect is not caused by gene-specific repression through CCCTC-binding factor (CTCF)
but instead by aberrant chromatin compaction. Treatment with an HDAC inhibitor was found to effectively
reactivate PUMA expression on the mRNA and protein level and to revert resistance to DNA damage–induced cell
death. Ectopic expression of PUMA was found to resensitize a panel of RCC cell lines to four different DNA-
damaging agents tested. Remarkably, all RCC cell lines analyzed were wild-type for p53, and a knockdown was
likewise able to sensitize RCC cells to acute genotoxic stress. Taken together, our results indicate that DNA
damage resistance in RCC is reversible, involves the p53-PUMA axis, and is potentially targetable to improve the
oncological outcomes of RCC patients.
Neoplasia (2014) 16, 1028–1035Introduction
Patients with metastatic renal cell carcinoma (RCC) have, with a few
exceptions, no curative options. Tyrosine kinase inhibitors have
successfully been introduced into the clinical care of patients with
advanced clear cell RCC, but most patients experience a progression-
free survival benefit of only 12 to 14 months. Additional treatment
approaches are hence urgently needed [1]. RCCs are commonly
resistant to conventional anticancer therapies such as radiotherapy
and chemotherapy. The underlying molecular mechanisms are, with
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[2], poorly understood.
On the molecular level, chemo- or radiotherapy is believed to
function mainly through the induction of DNA damage. In
particular, DNA double-strand breaks (DSBs) are highly toxic and
trigger an acute cellular response. After induction of a DNA DSB, a
cascade of events is initiated to halt cell cycle progression and activate
DNA repair mechanisms, which, in the case of a DSB, involve
nonhomologous end joining or homology-directed repair. If the
damage is too severe to be repaired, cells either enter premature
senescence or undergo apoptosis [3]. Activation of p53 has long been
shown to be a key event in this scenario, and a number of critical
downstream mechanisms involved in different branches of the p53-
mediated response to DNA damage have been identified. Whereas
the cell cycle arrest involves, among others, the transcriptional
upregulation of the cyclin-dependent kinase (CDK) inhibitor
p21Cip1, p53-dependent apoptosis involves genes such as PUMA,
NOXA, and BAX, which participate in the mitochondrial pathway of
apoptosis [4].
The BH3-only protein PUMA has been identified as a key
regulator of p53-dependent and -independent apoptosis following
genotoxic insults [5–7]. PUMA binds and inhibits antiapoptotic
BCL-2 proteins, thereby relieving the inhibition of the proapoptotic
proteins BAK/BAX and inducing mitochondrial outer membrane
permeabilization [8]. Members of the BCL-2 network are
frequently disrupted in primary RCCs, and furthermore, functional
studies have shown that the profound DNA damage resistance of
this tumor type involves defects in p53-mediated proapoptotic
signaling [9–12].
Here, we show that resistance to DNA damage–induced apoptosis
in RCC cells involves a disconnect between p53 activation and
upregulation of the proapoptotic protein PUMA that can be reverted
by histone deacetylase (HDAC) inhibition. Our results underscore
that the DNA damage resistance in RCC is reversible and may hence
translate into novel therapeutic concepts to improve patient outcome.
Material and Methods
Cells Culture and Transfections
Human embryonic kidney (HEK) 293 as well as Caki-1, Caki-2,
and A498 RCC cell lines were obtained commercially and maintained
as recommended by the distributor (CLS). The media were
supplemented with 10% fetal bovine serum, 50 U/ml penicillin,
and 50 mg/ml streptomycin (PAA). Plasmids used for transfections
were pCMV-p53 and pHA-PUMA (both from Bert Vogelstein
through Addgene) or empty control vectors. The target sequences for
siRNA-mediated knockdown of CCCTC-binding factor (CTCF) was
5’-ACCAGTGTGATTACGCTTGTA-3’ (Qiagen). For knockdown
of PUMA, pooled siRNA duplexes (Trilencer-27, OriGene,
SR308982) were used. For knockdown of p53, shRNA constructs
(TR320558; OriGene) were tested for maximum efficiency, and two
were selected for further experiments. Knockdown of protein
expression was confirmed by immunoblot analyses. For transient
transfections, 0.5 × 106 were transfected with 2 μg of plasmid DNA
or 15 μl of 20 μM annealed RNA duplexes (Neon Transfection
System, Life Technologies).
Antibodies and Reagents
Antibodies used were directed against ATM (MAT3-4G10/8;
Sigma), phospho-ATM S1981 (Rockland), CTCF (D31H2; CellSignaling), cleaved caspase-3 (5A1E; Cell Signaling), cyclin A (6E6;
Leica Biosystems), PARP-1 (Ab-2; Calbiochem), PUMA (Cell
Signaling or Millipore), p53 (DO-1; Santa Cruz), β-actin (AC-15,
Sigma), or GAPDH (FL-335; Santa Cruz). Neocarzinostatin (NCS),
cisplatin, gemcitabine, daunorubicin, and trichostatin A (TSA) were
obtained commercially (Sigma).
Flow Cytometry
After 72-hour treatment with NCS (200 ng/ml), 1 × 106 cells were
washed twice with PBS (1% BSA) and fixed with 70% ethanol, then
treated with 10 μg/ml RNAse A in PBS, and incubated at 37°C for
30 minutes before staining with 50 μg/ml propidium iodide for
30 minutes at 37°C. The cells were then analyzed using a
FACSCalibur flow cytometer and the ModFit software.
Immunofluorescence Microscopy
Cells were grown on coverslips and processed for immunofluores-
cence analysis as previously described. An antibody against PUMA (Cell
Signaling) was used at a 1:50 dilution followed by an Alexa Fluor 488–
conjugated donkey secondary antibody (Life Technologies). Cells were
analyzed using a DM5000B Leica fluorescence microscope.
Quantitative Polymerase Chain Reaction
Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) analysis was performed as previously described. Primers
to p53 (forward: 5′-GAGGTTGGCTCTGACTGTACC-3′,
reverse: 5′-TCCGTCCCAGTAGATTACCAC-3′), PUMA
(forward: 5′-ATGGCGGACGACCTCAAC-3′, reverse: 5′-
AGTCCCATGAAGAGATTGTACATGAC-3 ′ ) , p21 Cip1
(forward: 5′-TGTCCGTCAGAACCCATGC-3′, reverse: 5′-
AAAGTCGAAGTTCCATCGCTC-3′), CTCF (forward: 5′-
ACCAACCAGCCCAAACAGAAC - 3 ′ , r e v e r s e : 5 ′ -
GTATTCTGGTCTTCAACCTGAATGATA-3′), and GAPDH
(forward: 5′-ACAACTTTGGTATCGTGGAAGG-3′, reverse: 5′-
GCCATCACGCCACAGTTTC-3′) were obtained from Integrat-
ed DNA Technologies. GAPDH served as the reference gene for
relative quantification.
Cell Viability Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltratrazolium bro-
mide (MTT) assay (Molecular Probes) was used according to the
manufacturer's protocol. The absorbance at 570 nm was measured
using a Glomax Multi luminometer (Promega).
Cell Treatment and Immunoblotting
Cells were cultured in the presence of NCS (200 ng/ml),
cisplatin (10 μM), gemcitabine (10 μM), daunorubicin (0.5 μM),
and/or TSA (1 μM or 0.5 μM) for the time intervals indicated.
After treatment, adherent and floating cells were harvested, washed,
and processed for immunoblot analysis. Cells were lysed in NP-40
lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40)
containing protease inhibitors (10 μg/ml aprotinin, 10 μg/ml
leupeptin, 1 μM phenylmethylsulfonyl fluoride, and 2 μM vana-
date). Thirty or 50 μg of protein was separated by 10% SDS-PAGE
electrophoresis and blotted onto a nitrocellulose membrane.
Membranes were incubated with primary antibody at 4°C
overnight, washed with 0.1% Tween 20 in PBS thrice, and
incubated with horseradish peroxidase–conjugated secondary
antibody (Life Technologies) for 2 hours at room temperature.
Then, proteins were detected with an ECL detection system
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at least thrice.
Statistical Analysis
Student's t test for independent samples was used to compare
experimental groups. P values ≤ .05 were considered significant, and
all tests were performed two-sided. Data analysis was performed using
the SPSS software package (SPSS) or GraphPad Prism (GraphPad).
Results
DNA Damage–Induced Apoptosis, But Not Cell Cycle Arrest,
Is Impaired in Renal Cancer Cells
To explore cell fate decisions in response to DNA damage in
benign and malignant renal cells, we treated HEK293 and p53 wild-
type RCC cell lines Caki-2, Caki-1, and A498 with the radiomimetic,
DNA breakage–inducing compound NCS. NCS induced apoptosis
in HEK293 cells after 72 hours (30.5% vs 0.1% sub-G1 cells in
controls, Figure 1A). In contrast, Caki-2 cells failed to undergo
apoptosis and instead arrested mainly in the G2/M phase of the cellFigure 1. Caki-2 RCC cells are resistant to DNA damage–induced apop
in comparison to Caki-2, Caki-1, and A498 RCC cell lines after 72-hour
of apoptotic cells as evidenced by a sub-G1 population (arrows) in HEK
G2/M arrest instead. (B) Immunoblot analysis of HEK293 and Caki-
intervals indicated. Note the induction of apoptosis versus cell cycle a
A expression, respectively.cycle (37.9% vs 10.1% in controls, Figure 1A). We also analyzed
Caki-1 and A-498 cells, but these RCC cell lines showed a mixed
response with an increase of both apoptotic as well as cell cycle–
arrested cells (Figure 1A). Because of the virtually complete absence of
apoptosis, we decided to interrogate the defect in DNA damage–
induced apoptosis in Caki-2 cells in greater detail.
In immunoblot analyses, both cell lines, HEK293 and Caki-2,
showed an increase of phospho-ATM S1981, confirming an
induction of DNA damage by NCS (Figure 1B). HEK293 cells are
known to harbor high levels of constitutively active p53 [13], and we
did not detect any additional changes in the abundance of p53 in
HEK293 cells. Immunoblot analysis of PARP cleavage confirmed an
onset of apoptosis at 72 hours in HEK293 cells (Figure 1B). Why
cyclin A levels remained largely unchanged in these cells remains to be
determined, but cyclin A has been proposed to participate in
apoptosis in other cell types [14].
Apoptosis-resistant Caki-2 cells showed an increase of p53
expression, a decrease of cyclin A expression, but no PARP cleavage,
which confirms the flow cytometric results.tosis. (A) Representative flow cytometric analyses of HEK293 cells
treatment with 200 ng/ml NCS or left untreated. Note the increase
293, Caki-1, and A498 cells but not in Caki-2 cells, which undergo a
2 cells either untreated (0 hour) or treated with NCS for the time
rrest as evidenced by PARP cleavage (arrow) and reduction of cyclin
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the response to DNA-damaging agents between noncancerous and
malignant renal cells.
DNA Damage–Induced Upregulation of PUMA Is Defective in
Apoptosis-Resistant RCC Cells
We next asked whether the differences in the response to genotoxic
stress between HEK293 cells and Caki-2 cells involve a differential
activation of p53 downstream targets including the CDK inhibitor
p21Cip1 and the proapoptotic BH3-only protein PUMA.
Using qRT-PCR, we found that HEK293 showed an increase of
p21Cip1 and PUMA mRNA expression, whereas Caki-2 cells
upregulated only p21Cip1 but not PUMA mRNA (Figure 2A),
which is in line with both the cell cycle arrest phenotype and the
absence of DNA damage–induced apoptosis in the latter cell type.
To further corroborate the notion that Caki-2 cells are defective in
PUMA upregulation in response to DNA damage, we performed anFigure 2. Resistance to DNA damage–induced apoptosis is caused by
Caki-2 cells for p21Cip1 and PUMA mRNA expression after NCS trea
normalization to the housekeeping gene GAPDH. Mean and s
(B) Immunofluorescence microscopic analysis of PUMA expressio
Scale bar = 50 μm. (C) Immunoblot analysis of HEK293 and Caki-2 c
Caki-2 cells normalized to controls following transient overexpression
error of three experiments. (E) qRT-PCR analysis of HEK293 and Caki-2
for 72 hours or left untreated (control) and normalization to the houseke
experiments are shown. (F) Immunoblot analysis of Caki-2 cells trans
24 hours and treated with 200 ng/ml NCS for 72 hours or left untreateimmunofluorescence microscopic analysis. We found an increase of
PUMA expression in NCS-treated HEK293 cells, whereas PUMA
expression remained below the detection level in NCS-treated Caki-2
cells (Figure 2B).
Immunoblot analyses showed that HEK293 cells upregulated
PUMA in response to NCS, whereas the PUMA expression in Caki-2
cells remained at a significantly lower level despite a robust increase of
p53 expression (Figure 2C).
Taken together, these results show that the defect in DNA
damage–induced apoptosis in Caki-2 is associated with a defect to
upregulate PUMA expression to a proapoptotic level on the mRNA
and protein level despite p53 stabilization.
We next analyzed the effects of ectopically expressed PUMA in
Caki-2 cells to determine whether these cells are still responsive to
PUMA-induced cytotoxicity. Ectopically expressed PUMA, but not
p53, was found to significantly reduce cell viability at 48 hours
posttransfection (Figure 2D). These results suggest an impairment ofdefective PUMA upregulation. (A) qRT-PCR analysis of HEK293 and
tment with 200 ng/ml for 72 hours or left untreated (control) and
tandard errors of three independent experiments are shown.
n in cells after treatment with 200 ng/ml NCS or left untreated.
ells treated with NCS 72 hours or left untreated. (D) Cell viability of
(48 hours) of p53 or PUMA. Each bar represents mean and standard
cells for CTCFmRNA expression after NCS treatment with 200 ng/ml
eping gene GAPDH.Mean and standard errors of three independent
fected with siRNA duplexes targeting CTCF or control duplexes for
d.
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apoptosis as cause of the resistance of Caki-2 cells to DNA damage–
induced cell death.
We therefore asked whether the insulator protein and gene-specific
PUMA repressor CTCF [15] may be involved in the defect to
upregulate PUMA in response to DNA damage. CTCF mRNA
expression levels were unchanged in both cell types following DNA
damage (Figure 2E). Knockdown of CTCF did not lead to increased
PUMA expression or enhanced apoptosis (Figure 2F), which makes a
role of CTCF in PUMA repression in the cell system used here unlikely.Figure 3. HDAC inhibition restores PUMA expression and DNA dam
analysis of Caki-2 cells treated with 1 μM TSA for the indicated time
24 hours. Scale bar = 20 μm. (B) qRT-PCR analysis of PUMA mRNA
control for 24 hours. (C) Immunoblot analysis of Caki-2 cells treated w
of PUMA and induction of PARP cleavage following TSA treatment. (D
cleavage (arrow), and GAPDH after transfection with siRNA duplexes
with 1 μM TSA for 36 hours or left untreated. Note the suppression of
PUMA siRNA. (E) Relative cell viability (MTT) analysis of Caki-2 cells
followed by treatment with 1 μM TSA for 36 hours. (F) Trypan blue dy
a sublethal concentrationof TSA (0.5 μM) in comparison toDMSO-treat
for 24 hours with either DMSO, 200 ng/ml NCS, 0.5 μM TSA, or a co
(H) Immunoblot analysis of Caki-2 cells treated with 200 ng/ml NCS an
PUMA and induction of apoptosis as evidenced by PARP cleavage andPUMA-Induced Apoptosis Can Be Reactivated by
HDAC Inhibition
We next tested whether PUMA repression may be a consequence
of general chromatin compaction and analyzed the effect of HDAC
inhibition on PUMA expression using the HDAC class I and II
inhibitor TSA. We first used TSA as monosubstance at a 1-μM
concentration and found enhanced spontaneous apoptosis of Caki-2
cells beginning at 24 hours (Figure 3A) together with an increase of
PUMA mRNA (Figure 3B) and protein expression (Figure 3C). The
induction of apoptosis was confirmed by PARP cleavage (Figure 3C).age–induced apoptosis in Caki-2 cells. (A) Brightfield microscopic
intervals. Note appearance of cells with apoptotic morphology at
expression following treatment with 1 μM TSA or DMSO used as
ith 1 μM TSA for 24 hours or left untreated. Note the reexpression
) Immunoblot analysis of Caki-2 cells for p53, cyclin A, PUMA, PARP
targeting PUMA or control siRNA (24 hours) followed by treatment
PUMA upregulation and apoptosis by TSA in cells transfected with
after transfection with siRNA duplexes targeting PUMA (24 hours)
e exclusion assay of Caki-2 cells treated with 200 ng/ml NCS and/or
ed controls. (G) Brightfieldmicroscopic analysis of Caki-2 cells treated
mbination of 200 ng/ml NCS and 0.5 μM TSA. Scale bar = 20 μm.
d/or 0.5 μM TSA for 24 hours or left untreated. Note reexpression of
expression of cleaved caspase-3.
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induced cell death, we used siRNA and found that depletion of
PUMA led to a reduced induction of PARP cleavage (Figure 3D) and
a reduction in the loss of viability associated with TSA treatment at a
1-μM concentration (Figure 3E).
To explore synergistic effects between HDAC inhibition and acute
DNA damage, we decided to use a sublethal concentration of TSA
(0.5 μM, Figure 3F). Combination treatment of Caki-2 cells withNCS
and sublethal TSA concentration resulted in significant cytotoxicity
(Figure 3G). At the same time, PUMA expression was increased
together with an apoptotic response as evidenced by enhanced PARP
cleavage and cleaved caspase-3 expression (Figure 3H).
Collectively, these results show that PUMA expression and DNA
damage–induced apoptosis can be effectively reactivated in RCC cells
by HDAC inhibition.
PUMA and p53 Expression Determines the Sensitivity to Acute
DNA Damage in RCC Cells
We next asked whether the sensitivity of RCC cells to other DNA-
damaging agents than NCS could likewise be modulated by ectopic
expression of PUMA and what the role of p53 in this scenario would
be. In this context, it is important to emphasize that all three RCC cell
lines tested (Figure 1) are wild-type for p53 and that p53 was not
completely inactive but rather shifting cells toward a cell cycle arrest
by p21Cip1 induction (Figure 2A). Using transient overexpression of0
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Figure 4. PUMA and p53 expression modulates sensitivity of RCC
analysis of Caki-2, Caki-1, and A498 RCC cells following treatment with
daunorubicin (0.5 μM) for 24 hours after transient transfection with P
p53 or control shRNA (48 hours). Nontransfected cells are shown as co
**P ≤ .005, ***P ≤ .0005; Student's t test for independent samples, twPUMA and two independent siRNAs targeting p53, we analyzed the
consequences of these changes in PUMA or p53 expression in Caki-2,
Caki-2, or A498 RCC cells treated with either NCS or the
chemotherapeutic agents cisplatin, gemcitabine, or daunorubicin
(Figure 4). Under all conditions tested, ectopic expression of PUMA
was found to be associated with a significant increase of drug-induced
cytotoxicity (Figure 4). Likewise, knockdown of p53 by either one or
both siRNA duplexes was found to be associated with enhanced
cytotoxic effects. These results underscore the importance of the
PUMA-p53 axis in the global DNA damage sensitivity of RCC cells.
Discussion
RCC cells have long been known to be resistant to DNA damage–
induced apoptosis, but the underlying molecular mechanisms are not
fully understood. Here, we extend the spectrum of mechanisms
involved in RCC DNA damage resistance by demonstrating a
disconnect between p53 and upregulation of its downstream target
and key proapoptotic protein PUMA. We show that the deficiency in
PUMA upregulation is due to aberrant chromatin compaction and
that inhibition of HDACs can restore PUMA expression and
apoptosis in response to DNA damage. In addition, we found that
depletion of p53 can sensitize RCC cells to acute DNA damage–
induced cell death.
Almost all members of pro- and antiapoptoticmembers of the BCL-2
family of proteins have been shown to be altered in RCC [9–11,16,17].0
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cells to various DNA-damaging agents.Relative cell viability (MTT)
either NCS (200 ng/ml), cisplatin (10 μM), gemcitabine (10 μM), or
UMA (48 hours) or control plasmid, or two shRNAs to knockdown
ntrol. Asterisks indicate statistically significant differences (*P≤ .05,
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1034 Harnessing the p53-PUMA Axis in RCC Zhou et al. Neoplasia Vol. 16, No. 12, 2014The present report extends this knowledge by showing that the
disconnect between p53 and PUMA can be reverted by HDAC
inhibition. This finding has potential clinical relevance for the use of
HDAC inhibitors as sensitizing agents to chemo- or radiotherapy in
RCC. This notion is underscored by the finding that RCCs frequently
overexpress HDACs [18]. The role of altered histone modifications
other than acetylation as well as aberrant DNA methylation patterns,
frequent findings in RCC [19], in disrupting the p53-PUMA axis
requires further analyses. Another factor that could influence the
evolution of DNA damage resistance in RCC is the extensive
intratumoral heterogeneity of RCC [20]. Acute and relatively severe
exogenous DNA damage is likely to be an infrequent event during
malignant progression and rather associated with chemo- or radiother-
apy. How endogenous and low-intensity DNA damage, for example,
caused by DNA replication stress shapes RCC genomes and affects the
p53-PUMA axis remains to be determined. A limitation of our study is
that only one RCC line has been interrogated in detail for the role of
PUMA in apoptotic defects. Additional experiments in particular with
tumor-derived primary cell cultures and cell lines are hence needed.
Importantly, HDAC inhibitors have previously been successfully used
as apoptosis-sensitizing agents in RCC in the context of other
proapoptotic stimuli [21–24].
An initially unexpected finding was that depletion of p53 likewise
sensitized RCC cells to DNA-damaging agents. All cell lines tested
were wild-type for p53 and have an intact ability to undergo a cell
cycle arrest (Figure 1). Because results presented in the present study
underscore the dichotomy between cell cycle arrest and apoptosis in
RCC cells, it is possible that an impaired ability to halt cell cycle
progression in an acute and p53-dependent manner is an intrinsically
DNA damage–sensitizing event. Support for this notion stems from a
number of findings. First, targeted deletion of p53 has been shown to
sensitize cells to DNA strand break–induced cell death, which was
mimicked by p21Cip1 deficiency, suggesting that the inability to
upregulate this CDK inhibitor was responsible for enhanced
apoptosis [25]. Second, cells in which p53 stability and function
were compromised due to viral oncogene expression were likewise
sensitized to DNA damage–induced apoptosis, although p53-
independent mechanisms are likely to contribute [26]. Third, p53
has been implicated in cell fate decisions [27], and the inability to
arrest the cell cycle due to p53 deficiency may trigger proapoptotic
pathways for example through mitotic catastrophe [28].
Collectively, our results underscore that DNA damage resistance in
RCC is, in principle, reversible and may hence be targetable as part of
novel combination therapies with the goal to improve the oncological
outcomes of RCC patients.
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